[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632585":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Olmetec-Based Treatment Cohort",null,"Patients with stage 1 hypertension who are prescribed Olmetec® or Olmetec Plus® as part of routine clinical practice will be included. Patients will be followed prospectively to assess changes in nocturnal blood pressure and blood pressure variability using ambulatory blood pressure monitoring (ABPM). No intervention beyond standard clinical care will be applied.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Yun Jeong Kong","CONTACT","82-10-3206-5162","yjkong246@daewoong.co.kr",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":10,"country":23,"countryCode":10,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Multiple centers in Republic of Korea","RECRUITING","Seoul","South Korea",{"type":25,"coordinates":26},"Point",[27,28],126.9784,37.566,{"lat":28,"lon":27},[31],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100632585","observational-study-to-evaluate-the-efficacy-of-olmetec-tab-on-nocturnal-blood-pressure-control-in-patients-with-stage--hypertension-100632585",false,"NCT07515599","Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension","A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy of OLMETEC Tab. (or OLMETEC Plus Tab.) on Nocturnal Blood Pressure Control in Korean Patients With Stage Ⅰ Hypertension","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients diagnosed with stage 1 hypertension according to clinical guidelines\n* Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice\n* Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)\n* Patients who voluntarily agree to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Patients with secondary hypertension\n* Patients with severe hypertension requiring immediate pharmacological i-ntervention\n* Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs\n* Patients who are pregnant, planning to become pregnant, or breastfeeding\n* Patients with severe renal impairment or severe hepatic impairment\n* Patients who are unable to comply with study procedures, including ABPM\n* Patients who are deemed inappropriate for participation by the investigator","ALL","19 Years",{"count":44,"type":45},12000,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.",[49],"Stage 1 Hypertension",[51],"hypertension","2026-03-31",{"date":54,"type":55},"2026-04-07","ACTUAL",{"date":57,"type":55},"2025-09-17",{"date":59,"type":45},"2027-01-31",{"name":5,"class":6},1]